ATRA
Atara Biotherapeutics, Inc.
There isn't enough reported data to score ATRA yet.
ATRA Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Under pressure | |
| Strong |
ATRA's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
ATRA PE Valuation
ATRA has no meaningful PE right now: it lost money over the past year.
ATRA Forward outlook
There aren't enough analyst estimates for ATRA to show an outlook.
ATRA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$25.53 | +$44.22 |
| Q2 2024 | -$39.10 | +$34.65 |
| Q1 2024 | -$53.00 | -$0.75 |
| Q4 2023 | -$65.25 | -$9.25 |
| Q3 2023 | -$69.75 | -$8.00 |
| Q2 2023 | -$73.75 | -$10.00 |
| Q1 2023 | -$52.25 | +$38.75 |
| Q4 2022 | -$56.00 | +$34.75 |
ATRA is still losing money, but far less than before: $1.56 per share over the past year, against $141.75 at its worst in late 2019.
ATRA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.2M | -65% |
| Q2 2026 | $630K | -96% |
| Q1 2026 | $516K | -99% |
| Q4 2025 | $1.6M | -95% |
| Q3 2025 | $3.5M | -91% |
| Q2 2025 | $17.6M | -39% |
| Q1 2025 | $98.1M | +259% |
| Q4 2024 | $32.8M | +670% |
ATRA's revenue has slid since its 2025 peak: $1M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -243% | -139 points |
| Q2 2026 | -749% | -767 points |
| Q1 2026 | -653% | -692 points |
| Q4 2025 | -161% | -123 points |
| Q3 2025 | -104% | -49 points |
| Q2 2025 | 18% | +82 points |
| Q1 2025 | 40% | +154 points |
| Q4 2024 | -37% | +1373 points |
ATRA's operating margin was −243% last quarter, down 139 points from the same quarter a year ago.
ATRA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$879K | +$8.9M |
| Q2 2026 | -$3.3M | +$4M |
| Q1 2026 | -$3.1M | +$25.1M |
| Q4 2025 | -$5.7M | +$18.9M |
| Q3 2025 | -$9.8M | -$5.8M |
| Q2 2025 | -$7.3M | +$3.4M |
| Q1 2025 | -$28.1M | +$1.6M |
| Q4 2024 | -$24.6M | +$25.9M |
ATRA has burned cash in almost every quarter: −$13M over the past year, against −$70M the year before.
ATRA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.9% | +293K shares |
| 1 year | +25% | +3M shares |
| 3 years | +269% | +11.2M shares |
| 5 years | +319% | +11.7M shares |
| Available history | +647% | +13.3M shares |
ATRA has 15M diluted shares, up 25% from a year ago.
ATRA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -1.4x | Net Cash |
ATRA has more cash than debt.
ATRA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.3 | Neutral |
| Stochastic | 12.7 | Oversold |
ATRA's weekly RSI is 44 (neutral) and its Stochastic is 13 (oversold).
ATRA PE vs Healthcare Sector
ATRA has no meaningful PE right now: it lost money over the past year.
ATRA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.67 | 8.5% below |
| 20 week MA | $8.98 | 12% below |
| 50 week MA | $8.74 | 9.3% below |
| 100 week MA | $9.48 | 16% below |
| 200 week MA | $21.2 | 63% below |
ATRA is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
ATRA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $412.8 | $554.5 | +34% |
| 2021 | $554.5 | $432.8 | -22% |
| 2022 | $432.8 | $74.8 | -83% |
| 2023 | $74.8 | $12.8 | -83% |
| 2024 | $12.8 | $12.2 | -5.2% |
| 2025 | $12.2 | $17.3 | +42% |
| 2026 YTD | $17.3 | $7.93 | -54% |
ATRA has finished lower in four of the last six years. It's down 54% so far in 2026.